• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Drug Channels Acquired by HMP Global

News
Article

Adam Fein, founder of Drug Channels, said the acquisition will allow the company to upgrade its technology, grow the company and provide live and in-person events.

Adam J. Fein, Ph.D.

Adam J. Fein, Ph.D.

HMP Global, a healthcare education company, will acquire Drug Channels Institute. Founded in 2006 by Adam J. Fein, Ph.D., Drug Channels is a market intelligence company focused on the pharmaceutical industry. It provides webinars and industry reports on pharmaceutical economic issues and drug supply and distribution. Terms of the agreement were not disclosed.

As part of the integration, Drug Channels leadership will remain in place, with Fein becoming president, Drug Channels Institute, and Paula Fein assuming the role of vice president, business development.

Adam Fein is a well-known thought leader in the pharmaceutical industry providing insight and analysis on drug pricing, pharmacy benefit managers, the specialty drug market, drug reimbursement, and healthcare reform. He is known for his humor in making the industry more accessible for readers.

On a blog post on the Drug Channels website, Adam Fein said the acquisition will allow the company to upgrade its technology, grow the company and provide live and in-person events.

HMP produces in person and virtual medical education events and provides news and clinical information for healthcare providers. It produces about 50 journals/websites and 400 events and serves oncology, neurology, psychiatry and behavioral health, gastroenterology, cardiovascular, dermatology and rheumatology.

Related Videos
Video 9 -"Overcoming Implementation Barriers for Digital Therapeutics Adoption"
Video 6 - "Failing to Reach Ideal Diabetes Care: Equitable Doesn’t Mean Equal"
Video 5 - "Revising Diabetes Outcome Measures"
Video 6 - "Navigating Insurance Coverage for Prescription Digital Therapeutics"
Video 5 - "FDA Approval Pathway for Prescription Digital Therapeutics"
Video 8 - "Gaps in Evidence Generation for Digital Therapeutics"
Video 7 - "Adoption Lessons For Payers"
Video 10 - "Managing Self Care"
Video 3 - "Embracing and Improving Access to Technology Tools"
Related Content
© 2024 MJH Life Sciences

All rights reserved.